Type 1 diabetes and cardiovascular disease

Oliver Schnell, Francesco Cappuccio, Stefano Genovese, Eberhard Standl, Paul Valensi, Antonio Ceriello

Research output: Contribution to journalArticlepeer-review


The presence of cardiovascular disease (CVD) in Type 1 diabetes largely impairs life expectancy. Hyperglycemia leading to an increase in oxidative stress is considered to be the key pathophysiological factor of both micro- and macrovascular complications. In Type 1 diabetes, the presence of coronary calcifications is also related to coronary artery disease. Cardiac autonomic neuropathy, which significantly impairs myocardial function and blood flow, also enhances cardiac abnormalities. Also hypoglycemic episodes are considered to adversely influence cardiac performance. Intensive insulin therapy has been demonstrated to reduce the occurrence and progression of both micro- and macrovascular complications. This has been evidenced by the Diabetes Control and Complications Trial (DCCT) / Epidemiology of Diabetes Interventions and Complications (EDIC) study. The concept of a metabolic memory emerged based on the results of the study, which established that intensified insulin therapy is the standard of treatment of Type 1 diabetes. Future therapies may also include glucagon-like peptide (GLP)-based treatment therapies. Pilot studies with GLP-1-analogues have been shown to reduce insulin requirements.

Original languageEnglish
Article number156
JournalCardiovascular Diabetology
Issue number1
Publication statusPublished - Oct 28 2013


  • Cardiovascular disease
  • Type 1 diabetes

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine
  • Endocrinology, Diabetes and Metabolism
  • Medicine(all)


Dive into the research topics of 'Type 1 diabetes and cardiovascular disease'. Together they form a unique fingerprint.

Cite this